Furrer D - Search Results

1

Discontinuation of bisphosphonates in seniors: a systematic review on health outcomes.

Lamarre M, Marcotte M, Laurin D, Furrer D, Vedel I, Tourigny A, Giguère A, Carmichael PH, Martines R, Morais J, Kröger E. Lamarre M, et al. Among authors: furrer d. Arch Osteoporos. 2021 Sep 15;16(1):133. doi: 10.1007/s11657-021-01000-w. Arch Osteoporos. 2021. PMID: 34524561 Review.

2

Cannabis against chronic musculoskeletal pain: a scoping review on users and their perceptions.

Furrer D, Kröger E, Marcotte M, Jauvin N, Bélanger R, Ware M, Foldes-Busque G, Aubin M, Pluye P, Dionne CE. Furrer D, et al. J Cannabis Res. 2021 Sep 4;3(1):41. doi: 10.1186/s42238-021-00096-8. J Cannabis Res. 2021. PMID: 34481519 Free PMC article. Review.

3

Health Impacts and Characteristics of Deprescribing Interventions in Older Adults: Protocol for a Systematic Review and Meta-analysis.

Tremblay Z, Mumbere D, Laurin D, Sirois C, Furrer D, Poisblaud L, Carmichael PH, Farrell B, Tourigny A, Giguere A, Vedel I, Morais J, Kröger E. Tremblay Z, et al. Among authors: furrer d. JMIR Res Protoc. 2021 Dec 9;10(12):e25200. doi: 10.2196/25200. JMIR Res Protoc. 2021. PMID: 34889771 Free PMC article.

4

Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review.

Furrer D, Dragic D, Chang SL, Fournier F, Droit A, Jacob S, Diorio C. Furrer D, et al. Cancer Drug Resist. 2022 Nov 2;5(4):995-1015. doi: 10.20517/cdr.2022.63. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36627894 Free PMC article. Review.

5

Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.

Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Furrer D, et al. Clin Breast Cancer. 2018 Aug;18(4):e687-e694. doi: 10.1016/j.clbc.2017.11.012. Epub 2017 Nov 23. Clin Breast Cancer. 2018. PMID: 29275864

6

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.

Burguin A, Furrer D, Ouellette G, Jacob S, Diorio C, Durocher F. Burguin A, et al. Among authors: furrer d. PLoS One. 2020 Jun 25;15(6):e0234991. doi: 10.1371/journal.pone.0234991. eCollection 2020. PLoS One. 2020. PMID: 32584853 Free PMC article.

7

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C. Furrer D, et al. Diagn Pathol. 2013 Feb 4;8:17. doi: 10.1186/1746-1596-8-17. Diagn Pathol. 2013. PMID: 23379971 Free PMC article.

8

Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.

Furrer D, Sanschagrin F, Jacob S, Diorio C. Furrer D, et al. Am J Clin Pathol. 2015 Nov;144(5):686-703. doi: 10.1309/AJCPT41TCBUEVDQC. Am J Clin Pathol. 2015. PMID: 26486732 Review.

9

Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry for Breast Cancer.

Diorio C, Furrer D, Michaud A, Laberge S, Popa I, Jacob S, Provencher L, Hogue JC. Diorio C, et al. Among authors: furrer d. Anticancer Res. 2016 Jan;36(1):435-7. Anticancer Res. 2016. PMID: 26722078

10

Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C. Furrer D, et al. Anticancer Res. 2016 Sep;36(9):4661-6. doi: 10.21873/anticanres.11017. Anticancer Res. 2016. PMID: 27630309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters